Ovarian Cancer

>

Latest News

Final Analysis of Niraparib Does Not Show Significant OS Benefit in Recurrent Ovarian Cancer
Final Analysis of Niraparib Does Not Show Significant OS Benefit in Recurrent Ovarian Cancer

March 27th 2023

In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit. In updated findings of the ENGOT-OV16/NOVA trial, final overall survival data of niraparib maintenance therapy showed a benefit for patients with recurrent ovarian cancer; however, mature data showed no significant benefit.

Carolina Frailty Index Score Validated in Ovarian Cancer
Carolina Frailty Index Score Validated in Ovarian Cancer

March 27th 2023

Maintenance Niraparib Dose Modification Does Not Affect PFS in Ovarian Cancer
Maintenance Niraparib Dose Modification Does Not Affect PFS in Ovarian Cancer

March 27th 2023

Dual Checkpoint Blockade With Neoadjuvant Chemo Shows Benefit in Ovarian Cancer
Dual Checkpoint Blockade With Neoadjuvant Chemo Shows Benefit in Ovarian Cancer

March 27th 2023

HRQOL Not Affected by Cytoreductive Surgery Plus HIPEC in Ovarian Cancer
HRQOL Not Affected by Cytoreductive Surgery Plus HIPEC in Ovarian Cancer

March 26th 2023

Video Series
Video Interviews

More News